Latin America Sodium-Glucose Cotransport-2 Inhibitor Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 9.00 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Latin America Sodium-Glucose Cotransport-2 Inhibitor Market Analysis
The Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market size is estimated at USD 0.3 billion in current year, and is expected to reach USD 0.5 billion by forecast period, growing at a CAGR of 9% during the forecast period.
The COVID-19 pandemic has been testing the capacity to respond and adapt to populations, governments, and health systems worldwide. In the Latin America region, Brazil presented the first suspected and the first confirmed cases. Most Latin American countries failed to implement timely measures to protect individuals with diabetes, which may severely impact individuals, health systems, and economies.
The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, is acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, close to 10% of the total population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, and they accounted for close to 90% of the total diabetic population in 2021.
The COVID-19 pandemic benefited the Sodium-Dependent Glucose Cotransporter 2 market. Diabetes weakens the immune system, which is exacerbated by COVID-19. Diabetes patients are more likely to have significant problems than non-diabetics. During COVID-19, diabetic medicine manufacturers took care to ensure that pharmaceuticals were delivered to diabetes patients with the assistance of local governments. Novo Nordisk stated that Since the outbreak of COVID-19, their commitment to patients, staff and the communities in which they operate has not changed, and they will continue provide their medicines and devices to people with diabetes and other serious chronic conditions, protect the health of their employees, and support doctors and caregivers in the fight against COVID-19 in Latin America.
Latin America Sodium-Glucose Cotransport-2 Inhibitor Market Trends
Rising Diabetes Prevalence in Latin America Region
In Latin America, the incidence of type 1 diabetes ranges from 0.4 to 8.3 cases per 100,000 children under the age of 15, and the prevalence of type 2 diabetes ranges from 1.2% to 8%, with higher prevalence rates in urban areas. Diabetes is expected to increase by 38% in Latin America over the next decade, compared to a 14% increase in the population. By 2025, the total number of diabetes cases is expected to more than double and surpass the number of cases in the United States, Canada, and Europe.
Factors contributing to this increase include population aging and increased life expectancy, urbanization, and lifestyle changes among Native American populations. Diabetes treatment is available to only a minority of people in many places. Furthermore, type 2 diabetes is frequently diagnosed late in the disease's progression, resulting in 10-40% of patients having chronic complications at the time of diagnosis. Hospital costs account for most direct treatment costs, and diabetes mortality has increased significantly in some areas over the last two decades.
Therefore, owing to the factors above, the growth of the studied market is anticipated in the Latin America Region.
Mexico is Expected to Dominate the Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market over the forecast period
Among the Latin American countries, Mexico dominates around 72% of the total Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market in the current year. This is mainly due to the high diabetes prevalence in the country. In Mexico, the Mexican health system is managed by each state and local health secretariat and is governed by the MOH. Furthermore, in many towns where the public sector cannot meet people's requirements, partnerships with private organizations have been put in place to increase access to PHC.
SGLT-2 inhibitors, commonly known as gliflozins, are a medication used to treat type 2 diabetes by lowering high blood glucose levels. SGLT-2 inhibitors are important in managing cardiovascular risk factors such as blood pressure, glycemia, weight, cardiac function, and anti-inflammatory action. Technological advancements have increased, leading to several modifications in the SGLT-2 inhibitors or the formulations being developed.
According to Universal Health Coverage 2022, The four nations, leading, including Argentina, Brazil, Colombia, and Mexico, achieved an overall index of essential coverage of 76-77 percent, with households spending less than 25 percent of their income on health care and expanding access to primary healthcare systems and coverage for noncommunicable illnesses enhanced service coverage, while a rise in the number of qualified healthcare personnel enabled community outreach.
Latin America Sodium-Glucose Cotransport-2 Inhibitor Industry Overview
The Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market is highly consolidated, with a few significant manufacturers having a global market presence. The companies strengthen their market presence by getting approval in new forms.
Latin America Sodium-Glucose Cotransport-2 Inhibitor Market Leaders
-
Astrazeneca
-
Eli Lilly
-
Astellas
-
Bristol Myers Squibb
-
Janssen
*Disclaimer: Major Players sorted in no particular order
Latin America Sodium-Glucose Cotransport-2 Inhibitor Market News
- February 2023: AstraZeneca's Forxiga (dapagliflozin) has been approved in the European Union to extend the indication for heart failure with reduced ejection fraction to cover patients across the full spectrum of left ventricular ejection fraction, including HF with mildly reduced and preserved ejection fraction.
- April 2022: Nippon Boehringer Ingelheim's SGLT-2 inhibitor Jardiance (empagliflozin) obtained a label update from PMDA in Japan, allowing its use in patients with chronic heart failure with preserved ejection fraction (HFpEF) in addition to those with heart failure with reduced ejection fraction (HFrEF).
Latin America Sodium-Glucose Cotransport-2 Inhibitor Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. Market Segmentation
5.1 Drug
5.1.1 Invokana (Canagliflozin)
5.1.2 Jardiance (Empagliflozin)
5.1.3 Farxiga/Forxiga (Dapagliflozin)
5.1.4 Suglat (Ipragliflozin)
5.2 Geography
5.2.1 Brazil
5.2.2 Mexico
5.2.3 Rest of latin America
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Eli Lilly
7.1.2 Janssen Pharmaceuticals
7.1.3 Bristol Myers Squibb
7.1.4 Boehringer Ingelheim
7.1.5 AstraZeneca
7.1.6 Astellas
7.1.6.1 Other Key Players
- *List Not Exhaustive
7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Latin America Sodium-Glucose Cotransport-2 Inhibitor Industry Segmentation
With diet and exercise, SGLT2 inhibitors are a family of prescription drugs that the FDA has licensed for use in persons with type 2 diabetes to reduce blood sugar levels. The Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market is segmented by Drug (Invokana, Jardiance, Farxiga/Forxiga, and Suglat) and by Geography (Brazil, Mexico, Rest of Latin America). The report offers the value (in USD) and Volume (in Units) for the above segments.
| Drug | |
| Invokana (Canagliflozin) | |
| Jardiance (Empagliflozin) | |
| Farxiga/Forxiga (Dapagliflozin) | |
| Suglat (Ipragliflozin) |
| Geography | |
| Brazil | |
| Mexico | |
| Rest of latin America |
Latin America Sodium-Glucose Cotransport-2 Inhibitor Market Research FAQs
What is the current Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market size?
The Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market is projected to register a CAGR of 9% during the forecast period (2024-2029)
Who are the key players in Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market?
Astrazeneca, Eli Lilly, Astellas, Bristol Myers Squibb and Janssen are the major companies operating in the Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market.
What years does this Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market cover?
The report covers the Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Latin America Sodium-Glucose Cotransport-2 (SGLT-2) Inhibitor Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Latin America Sodium-Glucose Cotransport-2 Inhibitor Industry Report
Statistics for the 2024 Latin America Sodium-Glucose Cotransport-2 Inhibitor market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America Sodium-Glucose Cotransport-2 Inhibitor analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
